These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9205737)

  • 1. Ebrotidine. A new generation H2-receptor antagonist and gastroprotective agent. Introduction.
    Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):427-30. PubMed ID: 9205737
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
    Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
    Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
    Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
    Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
    Agut J; Sánchez JC; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):447-9. PubMed ID: 9205741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ebrotidine on gastric mucosal calcium channel activity.
    Slomiany BL; Liu J; Kawai T; Czajkowski A; Slomiany A
    Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ebrotidine--a nostrum for ulcer.
    Grover JK; Rathi SS; Vats V
    Trop Gastroenterol; 1997; 18(3):111-3. PubMed ID: 9385853
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ebrotidine].
    Elizalde JI
    Gastroenterol Hepatol; 1997 Feb; 20(2):65-7. PubMed ID: 9072206
    [No Abstract]   [Full Text] [Related]  

  • 12. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
    Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
    Palop D; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ebrotidine.
    Patel SS; Wilde MI
    Drugs; 1996 Jun; 51(6):974-80; discussion 981. PubMed ID: 8736619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
    Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroprotective and antisecretory effects of ebrotidine.
    Konturek SJ; Maczka J; Kaminski K; Sito E; Torres J; Oleksy J
    Scand J Gastroenterol; 1992 Jun; 27(6):438-42. PubMed ID: 1352908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
    Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
    Romero A; Gómez F; Villamayor F; Ballesta A; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
    Muñoz-Navas M; Honorato J; Reina-Ariño M; Márquez M; Herrero E; Villamayor F; Torres J; Roset PN; Fíllat O; Camps F; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
    Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
    Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.